title: Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL).
authors.affiliation: Laboratory of Lymphocyte Signaling and Oncoproteome, Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, and Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
authors.forename: Sabine
authors.initials: S
authors.lastname: Dondorf
authors.affiliation: Laboratory of Lymphocyte Signaling and Oncoproteome, Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, and Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany alexandra.schrader@uk-koeln.de.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Schrader
authors.affiliation: Laboratory of Lymphocyte Signaling and Oncoproteome, Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, and Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
authors.forename: Marco
authors.initials: M
authors.lastname: Herling
mesh_terms: D001562:Benzimidazoles / Q000008:administration & dosage*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D013601:T-Lymphocytes / Q000187:drug effects*
chemical_list: D001562:Benzimidazoles; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases